Breaking Bottlenecks in Life Sciences R&D with AI Innovation - with Aziz Nazha of Incyte Pharmaceuticals
R&D teams are starting to advance AI capabilities faster than they can translate them into measurable business value, creating mounting friction between scientific progress and operational reality. In this episode, Aziz Nazha, Global Head of AI Innovations Institute at Incyte Pharmaceuticals, examines how culture, talent, infrastructure, and expectation‑setting determine whether AI meaningfully improves drug discovery and development. He highlights the practical shifts required — from redesigning workflows to disciplined upskilling and targeted validation cycles — to ensure AI adoption accelerates …
ʻAʻole i kākau ʻia kēia ʻanuʻu
Hoʻohana i STT.ai e hoʻololi i kēia ʻāpana me AI. E loaʻa i ka huaʻōlelo pololei me ka ʻike ʻana i ka mea kākau, nā manawa, a me ka hoʻouna ʻana i nā ʻano like ʻole.